An Inside Health Policy article cited CAHC’s research that found that Medicare beneficiaries were already seeing increased premiums before the Biden administration announced the new discounted prices CMS achieved for the first round of drug price negotiations and that the insulin cap and requirements for prescription drug plans to add pharmacy price concessions to the negotiated prices for select drugs would further increase the premium increases.
